Kamal Fani - MD, Assistant Professor of Cardiac Anesthesiology Anesthesiology Research Center Shahid Beheshti University of Medical Sciences Tehran, Iran

The current COVID-۱۹ pandemic created a significant challenge for all human life aspects including the health sector. One of the most important challenges was how to find treatment for the disease. Till now, a long list of pharmaceuticals has been tested; mostly disappointing. However, the virus' incursion continues (۱).All the currently available pharmaceuticals used for the treatment of COVID-۱۹ are repurposed ones (۲); while, none have been promising yet and emerging drugs are inevitable. Molecular docking is a shortcut to the discovery of emerging repurposed drugs (۳). In this issue of the Journal of Cellular and Molecular Anesthesia, Saidijam et al. have proposed three main SARSCoV-۲ NTPase/Helicase inhibitors as potential pharmaceuticals for the treatment of COVID-۱۹, using molecular docking and dynamics simulation approach (۴). These three phenolic compounds (i.e. amentoflavone, theaflavin ۳'-gallate, and procyanidin) have been discovered from a long list of ۵۲ phenolic compounds (mostly flavonoids) using a drug discovery method (i.e. a molecular docking) to analyze their binding affinity to SARS-CoV-۲ NTPase/helicase.